Harms, 2022 - Google Patents
Endogenous CXCR4 antagonists: role in HIV-1 transmission and therapy of CXCR4-linked diseasesHarms, 2022
View PDF- Document ID
- 16601922356494183680
- Author
- Harms M
- Publication year
External Links
Snippet
CXCR4 is ubiquitously expressed within the human body and has various physiological functions including regulation of the immune system, development and homeostasis. Malfunction of the CXCR4/CXCL12 axis is involved in a variety of pathologies including …
- 102100002212 CXCR4 0 title abstract description 202
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7007333B2 (en) | Peptides with anti-inflammatory activity and compositions containing them | |
| Schiraldi et al. | HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 | |
| US12060401B2 (en) | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders | |
| ES2272058T3 (en) | USE OF AN ANTAGONIST ANTIBODY AGAINST THE ONCOSTATIN M INFLAMMATORY MEDIATOR (0SM). | |
| JP2021011502A (en) | Peptides with anti-inflammatory activity, and composition comprising the same | |
| Mangino et al. | HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2 | |
| JP2019104754A (en) | Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) | |
| JP2016526014A (en) | Interleukin-10 composition and use thereof | |
| JP2016519108A (en) | Method for using interleukin-10 for the treatment of diseases and disorders | |
| KR20150022800A (en) | Composition for preventing or treating cachexia | |
| JP2023015277A (en) | Cxcr4 binding molecules | |
| US9254309B2 (en) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation | |
| KR102654684B1 (en) | Modulating Gamma-C-Cytokine Activity | |
| JP2020501506A (en) | Anti-NKp46 antibody and therapeutic use thereof | |
| US20180335433A1 (en) | Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases | |
| CN114585384A (en) | Compositions and methods using C/EBP alpha sarRNA | |
| CN107810195B (en) | Recombinant clusterin and its use in the treatment and prevention of disease | |
| JP4405916B2 (en) | FAS peptidomimetics and uses thereof | |
| JP2022501319A (en) | Anti-Siglec antibody, pharmaceutical composition comprising it and its use | |
| US20220242964A1 (en) | Compositions and methods for regulating erythropoiesis | |
| SK287523B6 (en) | Use of a CC chemokine mutant, pharmaceutical composition containing the chemokine mutant, truncated and mutated human RANTES and method for producing the same | |
| Shilovskiy et al. | Role and Molecular Mechanisms of Alternative Splicing of Th2-Cytokines IL-4 and IL-5 in Atopic Bronchial Asthma | |
| US20230192794A1 (en) | Engineered interleukin-22 polypeptides and uses thereof | |
| Harms | Endogenous CXCR4 antagonists: role in HIV-1 transmission and therapy of CXCR4-linked diseases | |
| JP2022540877A (en) | Fusion toxin proteins for the treatment of diseases associated with CMV infection |